Wall Street brokerages expect that Dare Bioscience Inc (NASDAQ:DARE) will report earnings per share of ($0.31) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Dare Bioscience’s earnings. Dare Bioscience reported earnings per share of ($0.28) in the same quarter last year, which would suggest a negative year over year growth rate of 10.7%. The company is expected to report its next earnings report on Monday, May 13th.
On average, analysts expect that Dare Bioscience will report full-year earnings of ($1.29) per share for the current financial year, with EPS estimates ranging from ($1.47) to ($1.10). For the next year, analysts anticipate that the company will post earnings of ($1.33) per share, with EPS estimates ranging from ($1.80) to ($0.86). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Dare Bioscience.
Several research analysts have recently commented on DARE shares. ValuEngine raised Dare Bioscience from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Maxim Group reissued a “buy” rating and set a $3.00 price objective on shares of Dare Bioscience in a report on Thursday, April 4th.
In other Dare Bioscience news, Director Roger Hawley acquired 454,545 shares of the business’s stock in a transaction dated Thursday, April 11th. The stock was bought at an average price of $1.10 per share, with a total value of $499,999.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 19.00% of the stock is currently owned by insiders.
An institutional investor recently raised its position in Dare Bioscience stock. Citadel Advisors LLC boosted its position in Dare Bioscience Inc (NASDAQ:DARE) by 205.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 106,338 shares of the biotechnology company’s stock after buying an additional 71,470 shares during the quarter. Citadel Advisors LLC owned approximately 0.93% of Dare Bioscience worth $104,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 6.42% of the stock is currently owned by institutional investors.
Dare Bioscience Company Profile
Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.